Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 7.5% – Should You Buy?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) was up 7.5% during mid-day trading on Thursday . The company traded as high as $140.25 and last traded at $139.6050. 40,963 shares changed hands during trading, a decline of 85% from the average daily volume of 276,917 shares. The stock had previously closed at $129.84.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Chardan Capital reaffirmed a “buy” rating and set a $240.00 price objective on shares of Palvella Therapeutics in a research note on Thursday, May 21st. BTIG Research lifted their target price on Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Mizuho boosted their target price on Palvella Therapeutics from $205.00 to $250.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. HC Wainwright boosted their target price on Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Finally, Stephens restated an “overweight” rating and set a $220.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $199.53.

Palvella Therapeutics Stock Up 3.0%

The stock has a market cap of $1.92 billion, a PE ratio of -31.97 and a beta of -0.15. The business’s fifty day moving average is $118.25 and its 200 day moving average is $109.69.

Palvella Therapeutics (NASDAQ:PVLA) last issued its earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.30). As a group, analysts predict that Palvella Therapeutics, Inc. will post -5.26 EPS for the current year.

Insiders Place Their Bets

In related news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the transaction, the chief operating officer directly owned 2,154 shares of the company’s stock, valued at $238,512.42. This trade represents a 66.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. KBC Group NV acquired a new position in shares of Palvella Therapeutics during the 1st quarter worth $28,000. Group One Trading LLC raised its position in Palvella Therapeutics by 151.5% during the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after acquiring an additional 200 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Palvella Therapeutics in the third quarter valued at about $36,000. JPMorgan Chase & Co. lifted its holdings in shares of Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after purchasing an additional 3,242 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Palvella Therapeutics in the second quarter valued at approximately $85,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.